celecoxib has been researched along with Intervertebral Disc Degeneration in 5 studies
Intervertebral Disc Degeneration: Degenerative changes in the INTERVERTEBRAL DISC due to aging or structural damage, especially to the vertebral end-plates.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic low back pain is a common clinical problem in both the human and canine population." | 6.87 | Intradiscal application of a PCLA-PEG-PCLA hydrogel loaded with celecoxib for the treatment of back pain in canines: What's in it for humans? ( Beukers, M; Bos, C; Creemers, LB; de Leeuw, M; Grinwis, GCM; Meij, BP; Plomp, SGM; Tellegen, AR; Tryfonidou, MA; van Dijk, M; Willems, N, 2018) |
| "Intervertebral disc degeneration (IDD) has been identified as one of the predominant factors leading to persistent low back pain and disability in middle-aged and elderly people." | 5.91 | Low-dose celecoxib-loaded PCL fibers reverse intervertebral disc degeneration by up-regulating CHSY3 expression. ( Cao, P; Chen, H; Hu, B; Li, J; Liang, L; Wang, J; Wang, Y; Wei, L; Wu, J; Wu, X; Xiao, Q; Xie, X; Xu, C; Yang, C; Yu, W; Zang, F; Zhang, R; Zhang, T; Zheng, G, 2023) |
| "In summary, we have demonstrated a new use for the old drug Celecoxib that treats intervertebral disc degeneration by enhancing autophagy in nucleus pulposus cells and opening a door for treating other degenerative diseases." | 4.12 | Celecoxib activates autophagy by inhibiting the mTOR signaling pathway and prevents apoptosis in nucleus pulposus cells. ( Chen, W; Jiang, L; Lin, H; Lu, S; Wang, H; Wang, Z; Yasen, M; Zhuang, C, 2022) |
| "Chronic low back pain is a common clinical problem in both the human and canine population." | 2.87 | Intradiscal application of a PCLA-PEG-PCLA hydrogel loaded with celecoxib for the treatment of back pain in canines: What's in it for humans? ( Beukers, M; Bos, C; Creemers, LB; de Leeuw, M; Grinwis, GCM; Meij, BP; Plomp, SGM; Tellegen, AR; Tryfonidou, MA; van Dijk, M; Willems, N, 2018) |
| "Intervertebral disc degeneration (IDD) has been identified as one of the predominant factors leading to persistent low back pain and disability in middle-aged and elderly people." | 1.91 | Low-dose celecoxib-loaded PCL fibers reverse intervertebral disc degeneration by up-regulating CHSY3 expression. ( Cao, P; Chen, H; Hu, B; Li, J; Liang, L; Wang, J; Wang, Y; Wei, L; Wu, J; Wu, X; Xiao, Q; Xie, X; Xu, C; Yang, C; Yu, W; Zang, F; Zhang, R; Zhang, T; Zheng, G, 2023) |
| " After the hydrogel was shown to be biocompatible and safe, an in vivo dose-response study was performed in order to determine safety and efficacy of the pNIPAAM MgFe-LDH hydrogel for intradiscal controlled delivery of CXB." | 1.42 | Biocompatibility and intradiscal application of a thermoreversible celecoxib-loaded poly-N-isopropylacrylamide MgFe-layered double hydroxide hydrogel in a canine model. ( Craenmehr, EG; Creemers, LB; Dhert, WJ; Grinwis, GC; Kranenburg, HJ; Langelaan, ML; Meij, BP; Papen-Botterhuis, NE; Plomp, SG; Riemers, FM; Tellegen, AR; Tryfonidou, MA; Willems, N; Yang, HY, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W | 3 |
| Yasen, M | 3 |
| Wang, H | 3 |
| Zhuang, C | 3 |
| Wang, Z | 3 |
| Lu, S | 3 |
| Jiang, L | 3 |
| Lin, H | 3 |
| Wang, Y | 1 |
| Zheng, G | 1 |
| Xie, X | 1 |
| Yu, W | 1 |
| Wang, J | 1 |
| Zang, F | 1 |
| Yang, C | 1 |
| Xiao, Q | 1 |
| Zhang, R | 1 |
| Wei, L | 1 |
| Wu, X | 1 |
| Liang, L | 1 |
| Cao, P | 1 |
| Xu, C | 1 |
| Li, J | 1 |
| Hu, B | 1 |
| Zhang, T | 1 |
| Wu, J | 1 |
| Chen, H | 1 |
| Tellegen, AR | 3 |
| Willems, N | 2 |
| Beukers, M | 2 |
| Grinwis, GCM | 1 |
| Plomp, SGM | 1 |
| Bos, C | 1 |
| van Dijk, M | 1 |
| de Leeuw, M | 1 |
| Creemers, LB | 3 |
| Tryfonidou, MA | 3 |
| Meij, BP | 3 |
| Rudnik-Jansen, I | 1 |
| Miranda-Bedate, A | 1 |
| Bach, FC | 1 |
| de Jong, W | 1 |
| Woike, N | 1 |
| Mihov, G | 1 |
| Thies, JC | 1 |
| Yang, HY | 1 |
| Langelaan, ML | 1 |
| Grinwis, GC | 1 |
| Kranenburg, HJ | 1 |
| Riemers, FM | 1 |
| Plomp, SG | 1 |
| Craenmehr, EG | 1 |
| Dhert, WJ | 1 |
| Papen-Botterhuis, NE | 1 |
1 trial available for celecoxib and Intervertebral Disc Degeneration
| Article | Year |
|---|---|
Intradiscal application of a PCLA-PEG-PCLA hydrogel loaded with celecoxib for the treatment of back pain in canines: What's in it for humans?
Topics: Animals; Back Pain; Biocompatible Materials; Celecoxib; Chronic Pain; Cyclooxygenase 2; Dogs; Extrac | 2018 |
4 other studies available for celecoxib and Intervertebral Disc Degeneration
| Article | Year |
|---|---|
Celecoxib activates autophagy by inhibiting the mTOR signaling pathway and prevents apoptosis in nucleus pulposus cells.
Topics: Apoptosis; Autophagy; Celecoxib; Humans; Inflammation; Intervertebral Disc Degeneration; Nucleus Pul | 2022 |
Celecoxib activates autophagy by inhibiting the mTOR signaling pathway and prevents apoptosis in nucleus pulposus cells.
Topics: Apoptosis; Autophagy; Celecoxib; Humans; Inflammation; Intervertebral Disc Degeneration; Nucleus Pul | 2022 |
Celecoxib activates autophagy by inhibiting the mTOR signaling pathway and prevents apoptosis in nucleus pulposus cells.
Topics: Apoptosis; Autophagy; Celecoxib; Humans; Inflammation; Intervertebral Disc Degeneration; Nucleus Pul | 2022 |
Celecoxib activates autophagy by inhibiting the mTOR signaling pathway and prevents apoptosis in nucleus pulposus cells.
Topics: Apoptosis; Autophagy; Celecoxib; Humans; Inflammation; Intervertebral Disc Degeneration; Nucleus Pul | 2022 |
Low-dose celecoxib-loaded PCL fibers reverse intervertebral disc degeneration by up-regulating CHSY3 expression.
Topics: Animals; Celecoxib; Dinoprostone; Disease Models, Animal; Intervertebral Disc Degeneration; Mice; Ra | 2023 |
Intradiscal delivery of celecoxib-loaded microspheres restores intervertebral disc integrity in a preclinical canine model.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Action Preparations; Disease Models, Animal | 2018 |
Biocompatibility and intradiscal application of a thermoreversible celecoxib-loaded poly-N-isopropylacrylamide MgFe-layered double hydroxide hydrogel in a canine model.
Topics: Acrylic Resins; Animals; Biocompatible Materials; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyc | 2015 |